Three questions about antibiotic resistance: What would the world be like without antibiotics? Why are they so hard to produce? What are the alternatives?
- #Antibiotics
- #Antibiotic resistance
- #Vaccines
- #Phage therapy
- #Monoclonal antibodies
#1- What would a world without antibiotics look like?
32 years. That was the average life expectancy worldwide in 1900. By 2023, it had more than doubled to 73. This spectacular rise can be explained by several factors: improved living conditions, better nutrition, and major medical breakthroughs such as the use of vaccines and antibiotics.
Antibiotics in particular played a key part in reducing infant mortality and lowering the risk of infection during routine surgical procedures. It is easy to forget that a hundred years ago, before the introduction of antibiotics, a "routine" bacterial infection or a relatively mild injury could lead to severe or even fatal complications.
The widespread use of antibiotics from the mid-20th century onwards revolutionized modern medicine. But this therapeutic success came at a price, as it encouraged the emergence and spread of antibiotic-resistant bacteria. Although antibiotic resistance occurs through a process of natural selection, it is amplified by inappropriate prescription (antibiotics do not work for viral infections but are often prescribed to treat them), poor compliance with treatment regimens, and use for non-therapeutic purposes (e.g. as growth promoters for livestock).
See also
The rapid escalation in resistance is raising concerns that we may find ourselves back in a "pre-antibiotic world" where antibiotics are no longer effective. The risk is all the more acute because identifying and producing new antibiotics is increasingly difficult, and vanishingly few are currently reaching the market.
#2- Why is it so difficult to produce new antibiotics?
Penicillin, discovered in 1928 before becoming widely used from the 1940s onwards, paved the way for the "golden era of antibiotics," which continued until the mid-1960s. Several classes of antibiotics were discovered and manufactured during this period, but since then the momentum has slowed significantly.
In 2020, WHO reported that the prospects of developing new antibiotic agents were limited and that very few of the products in development were targeting the most critical resistant bacteria.
Producing new antibiotics is a considerable scientific challenge, for several reasons: many bacterial targets are already being used by existing treatments; novel molecules must be non-toxic for humans; and bacteria have an extensive repertoire of defense mechanisms that they can deploy to resist multiple drugs.
One of the main obstacles to producing new antibiotics is the cost: developing new molecules is expensive and requires years of research. Once antibiotics are on the market, they are generally prescribed for a short period. And they must be used sparingly, only to treat bacteria that are resistant to older antibiotics, to ensure their continued efficacy. But this means that the commercial prospects and potential return on investment for new antibiotics are not seen as attractive by major pharmaceutical companies, many of which have abandoned research in this field.
Yet some research is giving grounds for optimism. In a recent collaborative study, several Institut Pasteur laboratories developed an artificial intelligence model capable of indicating when an antibiotic acts on bacteria in an unprecedented way. This model could be particularly useful in future for identifying novel molecules of interest in future.
See also
#3- What are the alternatives to antibiotics?
Although producing novel antibiotics is proving to be a huge challenge, there are alternatives, some of which already exist and some of which are under development. The main alternatives are:
- Phage therapy
This involves the use of bacteriophages (or phages), viruses that selectively target and destroy bacteria but have no impact on other living organisms. Phages were discovered at the Institut Pasteur in 1917 by Félix d'Hérelle. Although d'Hérelle demonstrated their therapeutic potential, they were soon overtaken by antibiotics and fell into oblivion. Over the past two decades, the rise in antibiotic resistance has led to renewed interest in this approach. Scientists at the Institut Pasteur recently developed an artificial intelligence tool capable of selecting the best possible cocktail of phages based on the genome of the targeted bacteria.
- The CRISPR-Cas approach
This tool, which works like molecular scissors that can cut the chromosome of a target bacterium, could be used to specifically eliminate antibiotic-resistant pathogenic bacteria while preserving the bacteria in our microbiome that are beneficial for us.
- Better vaccine coverage for bacterial (and viral) infections
There are preventive vaccines for certain bacterial diseases, such as whooping cough, diphtheria, meningococcal meningitis and pneumococcal infections. Better vaccine coverage would lower the number of infections and reduce the need for antibiotics.
Vaccination against viral diseases is also important – for example, influenza vaccination reduces the number of influenza cases, leading to less antibiotic use (both antibiotics prescribed inappropriately to treat the influenza virus and antibiotics prescribed appropriately to treat secondary bacterial infections).
- Monoclonal antibodies
Monoclonal antibodies, currently used to treat SARS-CoV-2, could also be effective in neutralizing bacteria or their toxins.
These small molecules, part of the innate immune system in many living beings, act on the bacterial membrane to eliminate bacteria.
More generally, improving our understanding of the mode of action of antibiotics and the defense mechanisms employed by bacteria to resist them could lead to the development of new therapeutic tools. Recently, for example, by elucidating the precise mechanism used by certain antibiotics to enter Escherichia coli bacteria, scientists from the Institut Pasteur were able to improve the permeability and sensitivity of these bacteria to antibiotics. Research into bacterial immunity (the entire gamut of strategies used by bacteria to defend against viruses that infect them) is also a promising avenue that may reveal new mechanisms with therapeutic potential.
These different areas of research are not only wide-ranging; they are also complementary – and that is crucial, since tackling the most antibiotic-resistant bacteria will probably involve a combination of several therapies.
Research on antibiotic resistance comes under the "Infectious disease threats" scientific priority in the Pasteur 2030 Strategic Plan, aimed at fighting infectious diseases and resistance to antibiotics and other antimicrobial agents.
Sources:
Early transmissible ampicillin resistance in zoonotic Salmonella enterica serotype Typhimurium in the late 1950s: a retrospective, whole-genome sequencing study, The Lancet Infectious Diseases, November 29, 2017
Prediction of strain level phage–host interactions across the Escherichia genus using only genomic information, Nature Microbiology, October 31, 2024
Uridine as a potentiator of aminoglycosides through activation of carbohydrate transporters, Science Advances, September 5, 2025
Neutralizing human monoclonal antibodies that target the PcrV component of the type III secretion system of Pseudomonas aeruginosa act through distinct mechanisms, eLife, February 17, 2026
Deep learning recognises antibiotic modes of action from brightfield images, Nature Communications, September 8, 2026